AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37279855
Drug: Urinary-derived human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF; Pregnyl; Organon, Jersey City, NJ) added to standard aGVHD therapy
Trial: 37279855
Drug: Standard aGVHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard aGVHD therapy (methylprednisolone 48 mg/m2)
Trial: 37279999
Drug: Letermovir, 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir, 480 mg, orally daily (with acyclovir)
Trial: 37279999
Drug: Valganciclovir, 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valganciclovir, 900 mg, orally daily (adjusted for kidney function)
Trial: 37280022
Drug: Bedtime diuretics
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime diuretics
Trial: 37280022
Drug: Non-diuretics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-diuretics
Trial: 37280082
Drug: Pectoserratus and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectoserratus and interpectoral plane block combined with general anesthesia (ropivacaine 3.75 mg/mL and clonidine 3.75 µg/mL in 40 mL of 0.9% sodium chloride)
Trial: 37280083
Drug: 24-hour group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour group (last dose at 07:00 the day prior to surgery)
Trial: 37280083
Drug: 36-hour group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36-hour group (last dose at 19:00 2 days prior to surgery)
Trial: 37280275
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus cisplatin (GP) chemotherapy combined with immunotherapy
Trial: 37280584
Drug: 12-week remote
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week remote supervised videoconference-based intervention, consisting of 2 weekly 45-min group sessions with progressive resistance exercises
Trial: 37280643
Drug: Delpazolid 0
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 0 mg once daily for 16 weeks
Trial: 37280643
Drug: Delpazolid 400
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 400 mg once daily for 16 weeks
Trial: 37280643
Drug: Delpazolid 800
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 800 mg once daily for 16 weeks
Trial: 37280643
Drug: Delpazolid 1200
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 1200 mg once daily for 16 weeks
Trial: 37280643
Drug: Delpazolid 800
RxNorm normalized name: Delpazolid
DrugBank: Delpazolid (DB13077)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delpazolid 800 mg twice daily for 16 weeks
Trial: 37280688
Drug: Lovastatin (LOV)
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin (LOV) 200 mg
Trial: 37282666
Drug: Pralsetinib 400-mg
RxNorm normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pralsetinib 400-mg once-daily oral
Trial: 37282797
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (conventional speech therapy and singing intervention)
Trial: 37283558
Drug: Weaning policy/protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaning policy/protocol based on duration of opioid/sedative use
Trial: 37283558
Drug: IWS policy/protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IWS policy/protocol for patients on opioids/sedatives ≥ 72 hours
Trial: 37283627
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 μg/kg, single oral dose)
Trial: 37283943
Drug: Anti-SARS-CoV-2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-SARS-CoV-2 antibodies tested at baseline, 8 weeks, and 16 weeks.
Trial: 37283969
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL (135 μg) candidate vaccine
Trial: 37283969
Drug: 1.0 mL
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL (270 μg) candidate vaccine
Trial: 37283969
Drug: Candidate vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate vaccine (both dosages)
Trial: 37283977
Drug: LLDT-8 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLDT-8 0.5 mg daily
Trial: 37283977
Drug: LLDT-8 1
RxNorm normalized name: LLDT-8
DrugBank: PG-701 (DB12252)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LLDT-8 1 mg daily
Trial: 37284847
Drug: NK-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: NK-1 receptor antagonist (fosaprepitant 150 mg IV or aprepitant 130 mg IV)
Trial: 37284847
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no NK-1 receptor antagonist)
Trial: 37285081
Drug: Tirzepatide 2.5-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 2.5-10.0 mg
Trial: 37285081
Drug: Tirzepatide 2.5-15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide 2.5-15.0 mg
Trial: 37285113
Drug: MOTS-c peptide
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOTS-c peptide treatment
Trial: 37285278
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg once daily (o.d.)
Trial: 37285718
Drug: Eribulin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin monotherapy
Trial: 37285801
Drug: Cholecalciferol OTF
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol OTF strips (40,000 IU) administered for 12 weeks
Trial: 37285865
Drug: Talazoparib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talazoparib plus enzalutamide (talazoparib 0.5 mg + enzalutamide 160 mg)
Trial: 37285865
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus enzalutamide (placebo + enzalutamide 160 mg)
Trial: 37285925
Drug: Lotilaner ophthalmic
RxNorm normalized name: lotilaner ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner ophthalmic solution 0.25%
Trial: 37286048
Drug: 1 intravenous
RxNorm normalized name: Choline C 11 Intravenous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 intravenous dose of 24 mg dexamethasone (DX1)
Trial: 37286048
Drug: 2 intravenous
RxNorm normalized name: Rubidium Chloride Rb 82 Intravenous Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 intravenous doses of 24 mg dexamethasone (DX2)
Trial: 37286215
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine (M-M-R VaxPro)
Trial: 37286303
Drug: Tebentafusp (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebentafusp (alone or in combination)
Trial: 37286303
Drug: Tebentafusp with
RxNorm normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tebentafusp with checkpoint inhibitors
Trial: 37286312
Drug: Intravesical recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical recombinant BCG (rBCG: VPM1002BC) applied weekly for three instillations followed by four cycles of neoadjuvant cisplatin/gemcitabine every 3 weeks.
Trial: 37286312
Drug: Atezolizumab 1200 mg
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 1200 mg every 3 weeks started together with rBCG and given for four cycles, continued as maintenance therapy after surgery every 3 weeks for 13 cycles.
Trial: 37286319
Drug: Treatment-as-usual (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual (standard care) for mothers after CS.
Trial: 37286324
Drug: mFOLFIRINOX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX treatment with circadian-based telemonitoring-telecare platform
Trial: 37286324
Drug: mFOLFIRINOX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX treatment
Trial: 37286457
Drug: Radioligand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand treatment
Trial: 37286557
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (T-DXd) 6.4 mg/kg every 3 weeks in cohort A (HER2-positive, IHC 3+ or IHC 2+/ISH+).
Trial: 37287080
Drug: Current glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current glucocorticoid (GC) treatment
Trial: 37287080
Drug: Cumulative GC
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative GC dose and duration of use
Trial: 37287970
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg methylprednisolone intravenously for 3 consecutive days followed by tocilizumab (TCZ) monotherapy
Trial: 37288326
Drug: 1-hour infusion
RxNorm normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour infusion group
Trial: 37288326
Drug: 2-hour infusion
RxNorm normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-hour infusion group
Trial: 37288570
Drug: All medication
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All medication class regimens
Trial: 37288570
Drug: 4 or
RxNorm normalized name: Dex4 Orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 or more medication classes
Trial: 37288582
Drug: Neoadjuvant immunochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunochemotherapy (NAICT) with toripalimab (PD-1 inhibitor) and albumin paclitaxel/cisplatin (TTP)
Trial: 37289256
Drug: Geptanolimab (GB226)
RxNorm normalized name: Geptanolimab
DrugBank: Geptanolimab (DB16417)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Geptanolimab (GB226) 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Trial: 37289335
Drug: High hemoglobin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hemoglobin target (11-13 g/dl) with darbepoetin alfa
Trial: 37289335
Drug: Low hemoglobin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low hemoglobin target (9-11 g/dl)
Trial: 37289448
Drug: SB15 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB15 (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Trial: 37289448
Drug: AFL (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFL (2 mg every 4 weeks for the first 12 weeks, then every 8 weeks up to week 48)
Trial: 37289451
Drug: Preoperative Stereotactic
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative Stereotactic Radiosurgery (SRS) at a median dose of 15 Gy in 1 fraction or 24 Gy in 3 fractions, delivered at a median of 2 days before resection.
Trial: 37289541
Drug: Flu-IVIG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu-IVIG treatment in IBV-infected patients (n = 62)
Trial: 37289541
Drug: Flu-IVIG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu-IVIG treatment in IAV-infected patients (n = 50)
Trial: 37289666
Drug: Reserve antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reserve antibiotic (Group 5, largely colistin-based)
Trial: 37290035
Drug: Next-generation hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Next-generation hormonal agent (NHA)
Trial: 37290102
Drug: Propranolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (2 mg IV)
Trial: 37290102
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL normal saline IV)
Trial: 37290104
Drug: RRSO with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRSO with hormone use
Trial: 37290104
Drug: RRSO without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RRSO without hormone use
Trial: 37290461
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus cabozantinib (1200 mg intravenously every 3 weeks + 60 mg orally once daily)
Trial: 37290947
Drug: Clinical decision
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical decision rule (Marburg Heart Score combined with hs-cTnI-POCT, limit of detection 1.6 ng/L, cut-off value 3.8 ng/L)
Trial: 37290967
Drug: Rituximab de-escalation
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab de-escalation (various regimens including discontinuations and switches to oral treatment)
Trial: 37290996
Drug: INCB053914 (monotherapy)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Uzansertib (DB17571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB053914 (monotherapy)
Trial: 37291651
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg/h continuous infusion after initial loading doses of 0.5 μg/kg for 15 min
Trial: 37291651
Drug: Dexmedetomidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.75 μg/kg/h continuous infusion after initial loading doses of 0.75 μg/kg for 15 min
Trial: 37291651
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg/h continuous infusion
Trial: 37291651
Drug: Dexmedetomidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.75 μg/kg/h continuous infusion
Trial: 37291651
Drug: Midazolam 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.03 mg/kg at anaesthesia induction
Trial: 37291651
Drug: Dexmedetomidine 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.75 μg/kg
Trial: 37291677
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV imatinib twice daily for a maximum of seven days
Trial: 37291677
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg IV imatinib twice daily for a maximum of seven days in a subgroup of patients with high IL-6, TNFR1 and SP-D levels (n=20)
Trial: 37291731
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of propofol (1.4 mg/kg TBW)
Trial: 37291731
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of propofol (2.7 mg/kg TBW)
Trial: 37292376
Drug: Talimogene laherparepvec
RxNorm normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Talimogene laherparepvec (T-VEC) delivered by intralesional injection at 10
Trial: 37293030
Drug: d-serine +
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-serine + AudRem (100 mg/kg)
Trial: 37293067
Drug: Powder-based product
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder-based product (potato maltodextrin) mixed with expressed breast milk, administered daily for 4 weeks
Trial: 37293139
Drug: Guideline-directed medical
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed medical therapy (co-GDMT) as per European Society of Cardiology guidelines
Trial: 37294145
Drug: Multiple Electrolytes
RxNorm normalized name: Multiple Electrolytes Injection, Type 1, pH 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Electrolytes Solution (MES) (n = 351)
Trial: 37294145
Drug: Multiple Electrolytes
RxNorm normalized name: Multiple Electrolytes Injection, Type 1, pH 5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Electrolytes Solution (MES)
Trial: 37294245
Drug: Semaglutide (glucagon-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide (glucagon-like peptide-1 receptor agonist)
Trial: 37294477
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen 10 mg/kg every 6 hours, up to four doses per day
Trial: 37294604
Drug: Adapted interactive
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted interactive obesity treatment approach for 6 months
Trial: 37294609
Drug: Application of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 27 recommendations for intervention preparation and implementation in web-based games
Trial: 37294843
Drug: Same-day treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day treatment (same-day TB testing with same-day TB treatment if TB diagnosed; same-day ART if TB not diagnosed)
Trial: 37294843
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (initiating TB treatment within 7 days and delaying ART to day 7 if TB not diagnosed)
Trial: 37294914
Drug: Eltrombopag (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag (starting dose of 50 mg once daily to a maximum of 300 mg)
Trial: 37295035
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies (NAb) transfer ratio (TR)
Trial: 37295445
Drug: Lisocabtagene maraleucel
RxNorm normalized name: Lisocabtagene Maraleucel
DrugBank: Lisocabtagene maraleucel (DB16582)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10^6 cells, administered as a single intravenous infusion.
Trial: 37295810
Drug: Adjunctive coiling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive coiling
Trial: 37295836
Drug: Individualised duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised duration of antibiotic therapy (3 days after clinical improvement)
Trial: 37295836
Drug: Standard duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard duration of antibiotic therapy (10 days)
Trial: 37296922
Drug: Doxorubicin-ifosfamide chemotherapy
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin-ifosfamide chemotherapy and 5 × 5 Gy radiotherapy
Trial: 37296982
Drug: 5-fluorouracil-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil-based chemotherapy (e.g., FOLFIRINOX)
Trial: 37296982
Drug: Gemcitabine-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine-based chemotherapy (e.g., gemcitabine/nab-paclitaxel)
Trial: 37300484
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy for thyroid cancer
Trial: 37300888
Drug: UR without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UR without adjuvant chemotherapy
Trial: 37300888
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival in UR without adjuvant chemotherapy
Trial: 37301468
Drug: HPV ECHO+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV ECHO+ (AAT to providers plus recall notices to vaccine-declining parents)
Trial: 37301552
Drug: 4-week no
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week no manual therapy period
Trial: 37301885
Drug: Neo-T therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-T therapy with lymphodepletion
Trial: 37301885
Drug: Neo-T therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-T therapy without lymphodepletion
Trial: 37302348
Drug: Not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receiving active cancer therapy
Trial: 37302449
Drug: CurQD (curcumin-QingDai)
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CurQD (curcumin-QingDai) 3 g/d for 8 weeks
Trial: 37302533
Drug: Psilocybin-assisted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin-assisted group therapy (25 mg high-dose session)
Trial: 37302963
Drug: Mini-dose esketamine-dexmedetomidine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Mini-dose esketamine-dexmedetomidine combination
Trial: 37302963
Drug: Patient-controlled sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled sufentanil analgesia (4 μg kg)
Trial: 37303003
Drug: BIA method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA method for calculating CM dose
Trial: 37303003
Drug: TBW method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBW method for calculating CM dose